Heparin-induced thrombocytopenia: diagnosis and management

Heparin-induced thrombocytopenia (HIT) is an immune reaction in response to platelet factor 4-heparin complexes, which results in increased platelet activation and thrombocytopenia beginning on the 4th-5th day after heparin exposure induced by IgG antibody production. Platelet activation can lead to arterial thrombosis, but more commonly platelet microparticle formation contributes to venous thrombosis. Accurate diagnosis of HIT is based on the presence of clinical features, including a 50% fall in platelet count, appropriate timing of thrombocytopenia, development of new thrombosis despite thrombocytopenia and heparin therapy, and the absence of a more likely cause of thrombocytopenia. Documentation of an anti-PF4-heparin antibody is necessary, but is not sufficient to make the diagnosis since antibody formation occurs in a variety of clinical settings without the development of thrombocytopenia or thrombosis. Once HIT is suspected or confirmed, all forms of heparin should be discontinued and an alternative form of anticoagulation should be administered until the platelet count recovers. Treatment options include intravenous administration of argatroban, lepirudin, and bivalirudin; subcutaneous administration of fondaparinux has also been described. Warfarin therapy, if indicated, should be avoided until platelet recovery. Re-exposure to heparin can be avoided by use of alternative anticoagulants for most circumstances. Heparin-induced thrombocytopenia (HIT) has been the focus of increasing attention over the past 15-20 years. As interventions for HIT are developed, there is a need to accurately diagnose the condition, which can be challenging especially in severely ill patients.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Comprehensive HIT diagnosis and management review with argatroban, lepirudin and bivalirudin as primary alternative anticoagulants and fondaparinux as emerging option.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Explore cómo esta investigación se conecta con la práctica clínica

More peer-reviewed studies in Desarrollo de fármacos.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Hirudotherapy in Medicine and Dentistry — Jha K et al. (2015)
• Medicinal leech therapy (hirudotherapy): a brief overview — Singh A (2010)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Investigation of oxidant-antioxidant status in patients treated with hirudotherapy: an experimental study — Sarikan I, Savas H (2024)
• Leech therapeutic applications — Abdualkader A et al. (2013)
• Non-Occlusive Mesenteric Ischemia Due to Hirudotherapy: A Case Report — Akalın Ç, Ekmen N (2020)
• Leech therapy: a history — Hyson J (2005)

Browse all ASH-analysed research →